Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia

Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Li Li, Bao Nguyen, Tessa Seale, Donald Small

Blood (2023) 142 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2023-185759

Published: 2023

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Journal Articles

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2021) 138 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2021-149395

Published: 2021

Journal Articles

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, PhD, Jeejin Im, June H-J H-J Han, Kyu-Tae Kim, PhD, Jeong-Hyeok Yoon, PhD, Hanna Cho, PhD, Seung-Hye Choi, PhD, David Young, MD, Bao Nguyen, Ruiqi Zhu, PhD, Li Li, MD,PhD, Donald Small, MD, PhD, Taebo Sim, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139044

Published: 2020

Journal Articles

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-138374

Published: 2020

Journal Articles

High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations

Anna S Nam, MD, Kyu-Tae Kim, PhD, Ronan Chaligne, PhD, Franco Izzo, PhD, Chelston Ang, MS, Nathaniel Omans, MS, Alessandro Pastore, Justin Taylor, MD, Alicia Alonso, Wayne Tam, MD PhD, Ronald Hoffman, MD, Joseph Scandura, MDPhD, Raul Rabadan, PhD, Omar I Abdel-Wahab, MD, Peter Smibert, PhD, Dan A. Landau, MD PhD

Blood (2018) 132 (Supplement 1): 541.

https://doi.org/10.1182/blood-2018-99-119236

Published: 2018

Journal Articles

Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML

Annahita Sallmyr, Jinshui Fan, Kamal Datta, Kyu-Tae Kim, Dan Grosu, Paul Shapiro, Donald Small, Feyruz Rassool

Blood (2008) 111 (6): 3173–3182.

https://doi.org/10.1182/blood-2007-05-092510

Published: 2008

Includes: Supplemental data

Journal Articles

Prolonged Exposure to FLT3 Inhibitors Leads to Resistance Via Activation of Parallel Signaling Pathways.

Obdulio Piloto, PhD, Melissa Wright, BS, Patrick Brown, MD, Kyu-Tae Kim, PhD, Mark Levis, MD/PhD, Donald Small, MD/PhD

Blood (2006) 108 (11): 1380.

https://doi.org/10.1182/blood.V108.11.1380.1380

Published: 2006

Journal Articles

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

Obdulio Piloto, Melissa Wright, Patrick Brown, Kyu-Tae Kim, Mark Levis, Donald Small

Blood (2006) 109 (4): 1643–1652.

https://doi.org/10.1182/blood-2006-05-023804

Published: 2006

Includes: Supplemental data

Journal Articles

FLT3 Inhibitor Resistant Cells Show Different Downstream Signaling Pathway Changes.

Kyu-Tae Kim, PhD, Obdulio Piloto, BS, Donald Small, MD, PhD

Blood (2005) 106 (11): 4381.

https://doi.org/10.1182/blood.V106.11.4381.4381

Published: 2005

Journal Articles

Bad Phosphorylation Is Reduced in Response to Inhibition of Constitutively Activated FLT3.

Kyu-Tae Kim, PhD, Mark Levis, MD, PhD, Donald Small, MD, PhD

Blood (2005) 106 (11): 1367.

https://doi.org/10.1182/blood.V106.11.1367.1367

Published: 2005

Journal Articles

FLT3 Immunotherapy Can Eliminate Engraftment of ALL Cells in NOD/SCID Mice.

Obdulio Piloto, BS, Bao Nguyen, MS, Patrick Brown, MD, Kyu-Tae Kim, PhD, David Huso, PhD, Yiwen Li, PhD, Larry Witte, PhD, Daniel J. Hicklin, PhD, Donald Small, MD/PhD

Blood (2005) 106 (11): 869.

https://doi.org/10.1182/blood.V106.11.869.869

Published: 2005

Journal Articles

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Mark Levis, Kathleen M. Murphy, Rosalyn Pham, Kyu-Tae Kim, Adam Stine, Li Li, Ian McNiece, B. Douglas Smith, Donald Small

Blood (2005) 106 (2): 673–680.

https://doi.org/10.1182/blood-2004-05-1902

Published: 2005

Journal Articles

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

Kyu-Tae Kim, Kristin Baird, Joon-Young Ahn, Paul Meltzer, Michael Lilly, Mark Levis, Donald Small

Blood (2005) 105 (4): 1759–1767.

https://doi.org/10.1182/blood-2004-05-2006

Published: 2005

Journal Articles

Constitutive FLT3 Activation Results in Specific Changes in Gene Expression in Myeloid Leukemic Cells.

Kyu-Tae Kim, Kristin Baird, Sean Davis, Mark Levis, Obdulio Piloto, Li Li, Peili Chen, Paul Meltzer, Donald Small

Blood (2004) 104 (11): 1115.

https://doi.org/10.1182/blood.V104.11.1115.1115

Published: 2004

Journal Articles

EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces NOD/SCID Engraftment of AML Cell Lines and Primary Blasts.

Obdulio Piloto, B.S., Mark Levis, M.D./Ph.D., Li Li, Ph.D., Bao Nguyen, M.S., Kyu-Tae Kim, Ph.D., David Huso, Ph.D., Yiwen Li, Ph.D., Hongli Li, Ph.D., Mei-Nai Wang, Ph.D., Larry Witte, Ph.D., Daniel J. Hicklin, Ph.D., Donald Small, M.D./Ph.D.

Blood (2004) 104 (11): 2534.

https://doi.org/10.1182/blood.V104.11.2534.2534

Published: 2004

Journal Articles

EB10, an Anti-FLT3 Monoclonal Antibody, Selectively Targets ALL Cell Lines and Primary ALL Blasts without Interfering with Normal Hematopoiesis.

Obdulio Piloto, B.S., Patrick Brown, M.D., Li Li, Ph.D., Bao Nguyen, M.S., Kyu-Tae Kim, Ph.D., David Huso, Ph.D., Yiwen Li, Ph.D., Hongli Li, Ph.D., Mei-Nai Wang, Ph.D., Larry Witte, Ph.D., Daniel J. Hicklin, Ph.D., Donald Small, M.D./Ph.D.

Blood (2004) 104 (11): 2744.

https://doi.org/10.1182/blood.V104.11.2744.2744

Published: 2004

Journal Articles

FLT3/ITD Expression Increases Expansion, Survival and Entry into Cell Cycle of Human Hematopoietic Stem Cells.

Li Li, Ph.D., Obdulio Piloto, B.S., Kyu-Tae Kim, Ph.D., Zhaohui Ye, M.S., Bao Nguyen, M.S., Xiaobing Yu, M.D., Ph.D., Mark Levis, M.D., Ph.D., Linzhao Cheng, Ph.D., Donald Small, M.D., Ph.D.

Blood (2004) 104 (11): 484.

https://doi.org/10.1182/blood.V104.11.484.484

Published: 2004

NARROW

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations

Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML

Prolonged Exposure to FLT3 Inhibitors Leads to Resistance Via Activation of Parallel Signaling Pathways.

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

FLT3 Inhibitor Resistant Cells Show Different Downstream Signaling Pathway Changes.

Bad Phosphorylation Is Reduced in Response to Inhibition of Constitutively Activated FLT3.

FLT3 Immunotherapy Can Eliminate Engraftment of ALL Cells in NOD/SCID Mice.

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

Constitutive FLT3 Activation Results in Specific Changes in Gene Expression in Myeloid Leukemic Cells.

EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces NOD/SCID Engraftment of AML Cell Lines and Primary Blasts.

EB10, an Anti-FLT3 Monoclonal Antibody, Selectively Targets ALL Cell Lines and Primary ALL Blasts without Interfering with Normal Hematopoiesis.

FLT3/ITD Expression Increases Expansion, Survival and Entry into Cell Cycle of Human Hematopoietic Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only